Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials

Zhang, Jing; Yang, Jie; Chang, Xueli; Zhang, Canfei; Zhou, Huijie; Liu, Ming

doi:10.1179/1743132812y.0000000022

Cited by 32 publications

(17 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding supports our conclusion. In the study by Zhang et al, [6] their investigation stated that ozagrel is effective for the improvement of neurological impairment for AIS patients. Feng et al [31]showed that an effective treatment trend of edaravone for acute ischemic stroke.…”

Section: Discussionmentioning

confidence: 99%

“…Guideline from the American Heart Association/American Stroke Association for the patients' early management of acute ischemic stroke remains multifaceted, and includes several aspects of care that have not been tested in clinical trials [4]. Although data from some experimental and human studies have suggested that edaravone and Sodium ozagrel, the neuroprotective agent, may be beneficial for people with acute ischemic stroke, It has been widely used in China to treat stroke [5], [6], the comparisons of these drugs or combined treatments were unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Therapies for Acute Ischemic Stroke in China: A Network Meta-Analysis of 13289 Patients from 145 Randomized Controlled Trials

et al. 2014

View full text Add to dashboard Cite

BackgroundMany of these therapies have been compared against placebos, but have not been directly compared against each other. To evaluate the efficacy and safety of several commonly used drugs for AIS directly or indirectly.MethodsA systematic literature review was performed to identify randomized controlled trials (RCTs) published prior to April 2013 for AIS therapies. The primary outcome measures were the National Institutes of Health Stroke Scale (NIHSS) scores and the clinical effective rate. A fixed-effects meta-analysis and meta-regression are performed; lastly, performed a mixed treatment comparison was performed through the Bayesian methods.ResultsOutcome of Efficacy of therapies for acute ischemic stroke are as followed: All of the therapies mentioned above yielded results a more effective result than placebo, Sodium ozagrel (RR 3.86, 95%CI 3.18–4.61); Sodium ozagrel + edaravone (RR 9.60, 95%CI 7.04–13.06); Edaravone (RR 4.07, 95%CI 3.30–5.01); Edaravone + Kininogenase (RR 15.33, 95%CI 10.03–23.05). The significant difference in efficacy between edaravone monotherapy and Sodium ozagrel + edaravone was evident (RR 0.43, 95%CI 0.08–0.61) and was also significant between efficacy of edaravone + Kininogenase and Sodium ozagrel (RR 4.00, 95%CI 2.47–6.24). The differences between the risk and benefit were not significant when comparing Sodium ozagrel and edaravone or edaravone + Kininogenase and Sodium ozagrel + Edaravone for AIS. Outcome of the defect of neurological function: Placebo served a significant difference in treating the defects of neurological function compared with Sodium ozagrel (WMD = −3.11, 95%CI −4.43 to −1.79), Sodium ozagrel + edaravone (WMD = −6.25, 95%CI −7.96 to −4.54) and Edaravone + Kininogenase (WMD = −3.47, 95%CI −5.73 to −1.21).ConclusionsIt provides that the efficacy of edaravone monotherapy in treatment was not more effective than Sodium ozagrel + edaravone.The efficacy of edaravone + Kininogenase monotherapy in treatment was more effective than Sodium ozagrel. Edaravone + Kininogenase and Sodium ozagrel + Edaravone appeared the most effective treatments. And Sodium ozagrel, Sodium ozagrel + edaravone, Edaravone + Kininogenase can improve the nerve dysfunction.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Therapies for Acute Ischemic Stroke in China: A Network Meta-Analysis of 13289 Patients from 145 Randomized Controlled Trials

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Developing a TXS inhibitor is a promising strategy for protecting against cerebral ischemic stroke (Kontogiorgis and Hadjipavlou-Litina, 2010). Ozagrel is a conventional TXS inhibitor clinically effective for the prevention and treatment of ischemic cerebral disease Zhang et al, 2012;Rink and Khanna, 2011), and it is administered by intravenous (i.v.) injection.…”

Section: Introductionmentioning

confidence: 99%

N2 ameliorates neural injury during experimental ischemic stroke via the regulation of thromboxane A2 production

Zhou

Huang

et al. 2014

Pharmacology Biochemistry and Behavior

View full text Add to dashboard Cite

“…Platelets in this manner are actived in the intense stage, which discharges neurotoxic and thrombogenic. it is important to investigate different medications with the possibility to improve the cerebral blood stream and secure cerebrum work [4]. Therapeutic properties of ozagrel are observed as to restraint of TXA2 synthase by Ozagrel on human [5].…”

Section: Introductionmentioning

confidence: 99%

Effects of Thioxanthene Containing Anti-Psychotic and Anti-Platelet Drug Combination on Mean Platelet Volume and Platelet Distribution Width in Rats

Bashir

Saleem

Anwer

et al. 2019

JPRI

View full text Add to dashboard Cite

Aim:To evaluate the combined and individual effects of thioxanthene containing antipsychotic and anti-platlet drug on Mean Platelet Volume (MPV) and Platelet Distribution Width (PDW) in rats. Methods: This investigational study comprised of 100 albino rats of both sexual orientation, they were of 300 g to 350 g. We got ten groups, in which each group consisted of 10 rats (n=10).Ozagrel was used as anti-platelet and Zuclopenthixol was used as thioxanthene containing antipsychotic. Rats were treated with defined doses of Ozagrel and thioxanthene containing antipsychotic (Zuclopenthixol) alone and in joined for three weeks (21 days). Blood test at 0, seventh, fourteenth and last day of study were taken. Mean Platelet Volume and Platelet Distribution Width were estimated from blood tests by using standard research center procedure. Results were accumulated and abridged by applying statistics. Correlation was framed between all days incentive to zero day values. Original Research ArticleResults: Anti-psychotic drug and antiplatelet drug both showed decrease in MPV with both doses highly significantly (p < 0.001) decrease associated with maximum doses alone and with combination group. In case of PDW all individual and minimum combination group showed increase in PDW values but significantly (p < 0.001) increase in maximum combination groups. Conclusion: Combination of both drugs can cause more decrease in MPV as compare to the individual and in case of PDW combination with maximum doses may cause decrease in values by opposing the results individual therapy. It indicated any Drug-Drug interaction between these two drugs regarding Mean platelet volume and Platelet distribution width.

show abstract

Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials

Cited by 32 publications

References 7 publications

Efficacy and Safety of Therapies for Acute Ischemic Stroke in China: A Network Meta-Analysis of 13289 Patients from 145 Randomized Controlled Trials

Efficacy and Safety of Therapies for Acute Ischemic Stroke in China: A Network Meta-Analysis of 13289 Patients from 145 Randomized Controlled Trials

N2 ameliorates neural injury during experimental ischemic stroke via the regulation of thromboxane A2 production

Effects of Thioxanthene Containing Anti-Psychotic and Anti-Platelet Drug Combination on Mean Platelet Volume and Platelet Distribution Width in Rats

Contact Info

Product

Resources

About